Wockhardt to Launch Generic Version of BPH Drug Uroxatral
Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 10mg extended release tablets of Alfuzosin hydrochloride, which is used in treatment of Benign Prostatic Hyperplasia or enlarged prostate. Alfuzosin is the generic name for the brand Uroxatral marketed in the United States by Sanofi-Aventis. Wockhardt is launching the product immediately.
According to IMS Health, the total market for this product in the US is about $81.5 million. A substantial portion of men above the age of 60 suffer from BPH. Wockhardt also markets other drugs in the same therapeutic group in the US.
"Developing extended release formulation has been a core competency of Wockhardt's R&D over the years," said Dr. Habil Khorakiwala, Wockhardt Founder Chairman & Group CEO. "Extended Release Alfuzosin is yet another product in the NDDS technology space," he further added.
In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products has reaped the advantage of being an early entrant.
Wockhardt will be manufacturing the Alfuzosin hydrochloride API in its facility at Ankleshwar, India and the extended-release tablets of Alfuzosin at its facility in Aurangabad, India. The technology for the API and the capsules were developed in-house.
Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 75% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 164 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capabilities in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 7,900 people from 21 different nationalities.
Uroxatral is a registered trademark of Sanofi-Aventis.
Source: Wockhardt via PR Newswire